700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ ReadersThis Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Case Report Open Access
Background: Although alcohol use disorders and induced disorders are common in the world, however, only few medications, naltrexone, acamprosate, disulfiram, topiramate and baclofen are recommended for the reduction and cessation of alcohol withdrawal craving. Therefore it is required to develop new medications. Objective: To test the efficacy of low dose of buprenorphine on the reduction or cessation of alcohol withdrawal craving. Method: To evaluate the competence of four mg of buprenorphine in the treatment of alcohol craving in a case. Results: Buprenorphine administration was associated with ending of alcohol craving. In addition, buprenorphine was well endured. Discussion: Our findings demonstrated that buprenorphine has fast-acting and sustained anti-alcohol craving properties. This effect should be replicated in randomized, double-blind, placebo-controlled trials. Conclusion: To our understanding obvious effect of buprenorphine in this condition has not been issued yet.